menu
    • menu
    [{"orgOrder":0,"company":"Glycotope","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2025","type":"Acquisition","leadProduct":"DS-3939","moa":"TA-MUC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Glycotope","amount2":0.13,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Intravenous Infusion","sponsorNew":"Glycotope \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"Glycotope \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"DS-3939","moa":"TA-MUC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sankyo \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for DS-3939

    Menu

    DS-3939

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Glycotope

                            Germany arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Glycotope

                            Germany arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DS-3939

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Daiichi Sankyo

                            Deal Size : $132.5 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Daiichi Sankyo Acquires Anti-TA-MUC1 Antibody IP Rights from Glycotope

                            Details : Daiichi acquires the TA-MUC1 antibody, gatipotuzumab to advance the clinical development of DS-3939. It is being evaluated for the treatment of neoplasms.

                            Product Name : DS-3939

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            January 13, 2025

                            Lead Product(s) : DS-3939

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Daiichi Sankyo

                            Deal Size : $132.5 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Daiichi Sankyo

                            Japan arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Daiichi Sankyo

                            Japan arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DS-3939

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DS-3939 Enters Clinical Development in Patients Across Several Types of Advanced Solid Cancers

                            Details : DS-3939 is an investigational potential first-in-class TA-MUC1 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, which is investigated for the treatment of advanced solid tumors.

                            Product Name : DS-3939

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            July 09, 2023

                            Lead Product(s) : DS-3939

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth